TG Therapeutics advances BRIUMVI beyond MS with positive myasthenia gravis data
TG Therapeutics (NASDAQ:TGTX) reported positive topline results from an early-stage clinical evaluation of a subcutaneous formulation of its flagship therapy, BRIUMVI, in patients with myasthenia gravis, marking a significant milestone in the company’s strategy to expand the drug's utility beyond its approved indication for multiple sclerosis.
Alongside the early-stage clinical readout, the New York-based biotechnology firm initiated a potentially registration-directed Phase 2 clinical trial.
The newly launched study utilizes a novel sequential treatment framework designed to evaluate subcutaneous BRIUMVI as a maintenance therapy following a brief initial induction cycle of efgartigimod, an established FcRn inhibitor.
In the completed Phase 1 cohort, which evaluated 11 adult patients with acetylcholine receptor (AChR) antibody-positive myasthenia gravis, the under-the-skin injection demonstrated an encouraging therapeutic response and was generally well tolerated by participants.
By week 24 of the study, 82% of patients achieved the Minimal Clinically Important Difference in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score, which is a standardized metric used to measure daily operational symptom severity.
The cohort demonstrated a mean 4.6-point improvement in their diagnostic score by the conclusion of the observation window, with a median time to initial clinical response of 30 days.
The subsequent Phase 2 study plans to enroll approximately 120 adult patients to further validate these findings under a randomized, placebo-controlled design.
By pairing the rapid symptom control typically offered by transient FcRn inhibition with the durable, long-term disease modification provided by TG Therapeutics’ B-cell depletion technology, corporate executives believe the combined protocol could establish a highly differentiated care paradigm.
The dual-action strategy aims to achieve sustained disease control while significantly reducing the chronic treatment burden often associated with long-term standalone therapies for the chronic neuromuscular condition.
The expansion into orphan neurodegenerative disorders comes as TG Therapeutics continues to see accelerating commercial momentum for its standard intravenous formulation of BRIUMVI, which is currently approved to treat relapsing forms of multiple sclerosis.
The company recently raised its full-year 2026 global revenue targets to approximately $925 million on the back of strong domestic commercial uptake, positioning its clinical pipeline expansion into broader autoimmune indications as a core vector for long-term growth.
